- Recruiting
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Updated: Sep 29, 2022
GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
Sponsor
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT05431608
Official Title: Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : June 24, 2022
Click here for details on ClinicalTrials.gov
GPRC5D-Targeted CAR T Cell MCARH109
Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109 (Code C176222)
Autologous Anti-GPRC5D CAR-T Cells MCARH109
Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109
Autologous GPRC5D-targeted CAR T Cells MCARH109
MCARH 109
MCARH-109
MCARH109